
In this episode, Jon Chee sits down with Sabrina Johnson, President and CEO of DARÉ Bioscience, to unpack the founding arc of a company built on a singular conviction: women's health is not a niche. Sabrina explains the choice to go public via reverse merger in 2017 to access capital in a space where only 1% of private healthcare investment funds women-specific conditions, and breaks down the groomed trail philosophy behind XACIATO, DARE to PLAY Sildenafil Cream, a pivotal Phase 3 contraceptive, and an ARPA-H-funded HPV treatment—all with 25 people and $75M+ in non-dilutive funding.
Podzilla Summary coming soon
Sign up to get notified when the full AI-powered summary is ready.
Free forever for up to 3 podcasts. No credit card required.

🧬 The Rule of Three: Career, Family & One Other Thing | Mati Gill (1/4)

🧬 From Reactive Data to Predictive Intelligence: Inside Convoke's Platform | Alex Telford (4/4)

🧬 Pharma's Coordination Tax & the 2 Paths That Could Actually Disrupt It | Alex Telford (3/4)

🧬 AI Psychosis, Coordination Tax & the Limits of LLMs | Alex Telford (2/4)
Free AI-powered recaps of The Biotech Startups Podcast and your other favorite podcasts, delivered to your inbox.
Free forever for up to 3 podcasts. No credit card required.